about
Risk factors and treatment for recurrent vulvar squamous cell carcinomaPOLE Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial CancerOn-line set-up corrections during radiotherapy of patients with gynecologic tumors.Survival after relapse in patients with endometrial cancer: results from a randomized trial.Outcome of high-risk stage IC, grade 3, compared with stage I endometrial carcinoma patients: the Postoperative Radiation Therapy in Endometrial Carcinoma Trial.Limited impact of intratumour heterogeneity on molecular risk assignment in endometrial cancer.Normative data for the EORTC QLQ-C30 and EORTC-sexuality items in the general Dutch population.Treatment preferences and involvement in treatment decision making of patients with endometrial cancer and clinicians.Five-year quality of life of endometrial cancer patients treated in the randomised Post Operative Radiation Therapy in Endometrial Cancer (PORTEC-2) trial and comparison with norm data.Sexual dysfunction and infertility as late effects of cancer treatment.Long-term outcome in endometrial carcinoma favors a two- instead of a three-tiered grading system.Prognostic significance of POLE proofreading mutations in endometrial cancer.The role of radiotherapy in endometrial cancer: current evidence and trendsSubstantial lymph-vascular space invasion (LVSI) is a significant risk factor for recurrence in endometrial cancer--A pooled analysis of PORTEC 1 and 2 trials.Rectal bleeding after radiation therapy for endometrial cancer.Long-Term Impact of Endometrial Cancer Diagnosis and Treatment on Health-Related Quality of Life and Cancer Survivorship: Results From the Randomized PORTEC-2 Trial.Prediction model for regional or distant recurrence in endometrial cancer based on classical pathological and immunological parametersPostoperative radiotherapy for Stage 1 endometrial carcinoma: long-term outcome of the randomized PORTEC trial with central pathology review.International brachytherapy practice patterns: a survey of the Gynecologic Cancer Intergroup (GCIG)ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: Diagnosis, Treatment and Follow-up.High-precision prostate cancer irradiation by clinical application of an offline patient setup verification procedure, using portal imaging.Variability in clinical target volume delineation for intensity modulated radiation therapy in 3 challenging cervix cancer scenarios.Consensus guidelines for delineation of clinical target volume for intensity-modulated pelvic radiotherapy in postoperative treatment of endometrial and cervical cancer.Chronic fatigue in Hodgkin lymphoma survivors and associations with anxiety, depression and comorbidityA nurse-led sexual rehabilitation intervention after radiotherapy for gynecological cancerImmunological profiling of molecularly classified high-risk endometrial cancers identifies POLE-mutant and microsatellite unstable carcinomas as candidates for checkpoint inhibition.Consensus guidelines for delineation of clinical target volume for intensity-modulated pelvic radiotherapy for the definitive treatment of cervix cancer.Persisting fatigue in Hodgkin lymphoma survivors: a systematic review.Gynecologic Cancer InterGroup (GCIG) consensus review for uterine and ovarian carcinosarcoma.Gynecologic Cancer InterGroup (GCIG) consensus review for uterine serous carcinoma.Nomograms for prediction of outcome with or without adjuvant radiation therapy for patients with endometrial cancer: a pooled analysis of PORTEC-1 and PORTEC-2 trials.Markers of the p53 pathway further refine molecular profiling in high-risk endometrial cancer: A TransPORTEC initiative.Sister Society Meeting on Global Education Development and Collaboration: Meeting Report.European Society of Gynaecologic Oncology Quality Indicators for Advanced Ovarian Cancer Surgery.Tumour-free margins in vulvar squamous cell carcinoma: Does distance really matter?Microsatellite instability derived JAK1 frameshift mutations are associated with tumor immune evasion in endometrioid endometrial cancer.Radiation therapy combined with hyperthermia versus cisplatin for locally advanced cervical cancer: Results of the randomized RADCHOC trial.Less-favourable prognosis for low-risk endometrial cancer patients with a discordant pre- versus post-operative risk stratification.Patients' and clinicians' preferences for adjuvant chemotherapy in endometrial cancer: an ANZGOG substudy of the PORTEC-3 intergroup randomised trial.Ruthenium-106 brachytherapy for choroidal melanoma without transpupillary thermotherapy: Similar efficacy with improved visual outcome.
P50
Q28072964-E471DDAE-9C63-4365-8D9C-75FDF85B9634Q28260529-5ADEEFDB-85BB-4897-895C-45A07F685D2DQ33179670-AF9FF035-0A54-4793-AA3A-9B09174E913AQ33186818-92DE6005-6D51-4E58-84D6-3AACA9AAAC92Q33200527-FEB13987-33A7-4FAA-945B-C2EF5C197557Q33648936-ED38F072-D384-475C-A674-C91C0F91A6B0Q33764072-8488C205-EAB6-48BD-92AD-0E97938F943BQ34051920-7681A134-60FF-4C06-93AF-52D58FE660FCQ34104000-7F40ECD6-78F1-45B0-8F5D-EAA49EC7988EQ34604454-443C2E49-1225-4715-AE9E-CD7C19613D0CQ34604617-27C1A9A1-0D7D-4E58-ABA3-5FE780588EA4Q34994583-1F911AFA-CAE4-4BEB-976F-89748954949EQ35539990-21917396-3E90-4D98-9016-E76E90CC73ADQ35655379-F925F318-AAF6-4518-9CDC-CE6C5B718616Q35744132-6356112C-E910-451C-94DF-D5FE94A344ADQ35831130-128D2557-5EF0-43BE-879C-DC40E43F7D7BQ36027067-C02BE0C5-A0DF-4DCD-85E8-BCB1CF86AA39Q36146046-8DF43BD7-36CF-442F-9D62-043ABB5C20D5Q36372115-4CDEDBCC-6E02-4DB8-A2E9-9F175F269E25Q36372293-1384EC56-3734-4CEE-BE3D-AB5096127CB9Q36799600-701FB5D1-F27E-4021-BC84-324BAB6DD814Q36945859-48AD036C-9370-4488-80EB-EC4DE6CDF187Q37013997-13DDEA97-08E8-4171-9BAC-CB194C421F03Q37594343-7DDFEDC2-9A53-4579-80D0-8F1B90D7779DQ37607272-F8FF8957-B37F-4A59-8772-668A0E12B490Q37705031-00FB7702-18E7-4FEE-9E93-B36CAD1A2C88Q37753408-948F46E6-A6BA-4E3A-A6CD-030883CC6F0FQ38111234-74F73AD8-E264-45A1-9426-D78F53529D2FQ38262340-32BCDD4D-F1BB-40E7-9307-913C1E50DA1CQ38262343-B27710A5-4F42-40B3-AB1D-946C8AE1B10CQ38354989-67382D0F-3B38-4218-A187-543B7BFD0E3DQ38703322-2DE659A7-8AB4-4CEC-B0C3-7D40EEF9E034Q38850318-4B17747C-4C46-4CA3-A96A-38447073ABD4Q38959554-87C537D7-F618-4016-AA58-53DCB9FD4762Q39517409-43280C2F-E059-4A56-85C3-FF4ED1A1CC3EQ39744257-7A5B789A-0A12-470C-9AA2-5FC48A668A62Q39981989-08DB74A9-2A05-41C0-973E-1A537181E8C6Q40240102-CF59EACC-8EAB-4D96-AA0D-5EEF8211C364Q40528968-41BB8EB3-0CE5-4AB7-BAB4-5CB240AE2F30Q40541968-06173869-11DD-4EB0-97BA-1A8103384A5D
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Carien L Creutzberg
@ast
Carien L Creutzberg
@en
Carien L Creutzberg
@es
Carien L Creutzberg
@nl
Carien L Creutzberg
@sl
type
label
Carien L Creutzberg
@ast
Carien L Creutzberg
@en
Carien L Creutzberg
@es
Carien L Creutzberg
@nl
Carien L Creutzberg
@sl
prefLabel
Carien L Creutzberg
@ast
Carien L Creutzberg
@en
Carien L Creutzberg
@es
Carien L Creutzberg
@nl
Carien L Creutzberg
@sl
P106
P31
P496
0000-0002-7008-4321